Division of Medical Oncology
University of Colorado Denver
12801 E. 17th Avenue
Aurora, CO 80010
Ph: (303) 724-3888
Fax: (303 724-3889 info@deptofmed.edu
Antonio Jimeno, M.D., Ph.D.
Assistant Professor
Education:
M.D.: University of Valladolid, Spain
Ph.D.: University Complutense, Madrid, Spain
University of Colorado Denver
School of Medicine
Division of Medical Oncology
Tel: (303) 724-2478
Fax: (303) 724-1111
e-mail: Antonio.Jimeno@uchsc.edu
Bio
Dr. Jimeno joined the UCDHSC Faculty in April 2008 as the Director of the Developmental Therapeutics/Pharmacodynamic Laboratory and as a member of the Drug Development Program. He trained in Internal Medicine and Medical Oncology at the University Hospital 12 de Octubre in Madrid, Spain. After completing his training as a clinical researcher in the context of a Drug Development Clinical Fellowship at Johns Hopkins from 2003 to 2006, Dr. Jimeno joined the Faculty at Johns Hopkins as Instructor of Oncology in July 2006.
Research
Dr. Jimeno has developed an interest in integrating preclinical research, drug development, and clinical research. He has made a special emphasis in 1) developing better preclinical models, 2) determining predictors of response, and 3) devising ways to integrate that knowledge into clinical trials to individualize anti-cancer therapy. His concomitant work in the laboratory and the clinic has materialized in the form of novel inventions (drugs and biomarkers) that are currently the subject of prospective clinical testing. His clinical interest is Head and Neck and Upper Gastrointestinal cancer. He has been recognized for his research efforts with an ASCO Young Investigator Award in 2005, and two ASCO Merit Awards in 2004 and 2006.
Publications Jimeno A, Tan AC, Coffa J, NV Rajeshkumar, Kulesza P, Rubio-Viquira B, Wheelhouse J, Diosdado B, Messersmith WA, Maitra A, Iacobuzio-Donahue C, Meijer GA, Garcia ML, Tan AC, Varela-Garcia M, Hirsch F, Gerrit M, Hidalgo M. Coordinated activation of the EGFR pathway predicts sensitivity to EGFR inhibition in pancreatic cancer. Cancer Res 2008, April 15, 68(8). Jimeno A, Kulesza P, Kincaid E, Bouraoud N, Chan A, Forastiere A, Brahmer J, Clark D, Hidalgo M. c-fos assessment as a novel tool to evaluate efficacy of antiEGFR therapy. Cancer Res 2006, 66(4):2385-2390. Jimeno A, Rubio-Viqueira B, Amador ML, Oppenheimer D, Bouraoud N, Kulesza P, Sebastiani V, Maitra A, Hidalgo M. Epidermal growth factor receptor (EGFR) dynamics influences response to EGFR targeted therapies. Cancer Res 2005, 65(8):3003-3010.
Funding
ASCO Yound]g Investigator Award
Pending NIH-R21 application